NICE draft guidance recommends siponimod for treating secondary progressive multiple sclerosis

Friday, 16 October 2020

NICE has issued draft guidance which now recommends siponimod (also called Mayzent and made by Novartis) for treating secondary progressive multiple sclerosis (MS).

More......